---
title: "Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia | NBIX Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285377822.md"
description: "Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia | NBIX Stock News"
datetime: "2026-05-06T04:30:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285377822.md)
  - [en](https://longbridge.com/en/news/285377822.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285377822.md)
---

# Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia | NBIX Stock News

Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia | NBIX Stock News

### Related Stocks

- [NBIX.US](https://longbridge.com/en/quote/NBIX.US.md)

## Related News & Research

- [Neurocrine’s New Tardive Dyskinesia Trial Adds Fresh Optionality for NBIX Investors](https://longbridge.com/en/news/286946226.md)
- [Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics | NBIX Stock News](https://longbridge.com/en/news/286773551.md)
- [Neurocrine Unveils New INGREZZA Findings In Mild Tardive Dyskinesia At APA 2026; Closes Soleno Deal](https://longbridge.com/en/news/286873474.md)
- [Advisors Preferred LLC Purchases New Position in Neurocrine Biosciences, Inc. $NBIX](https://longbridge.com/en/news/285037789.md)
- [Horizon Investments LLC Buys 16,474 Shares of Neurocrine Biosciences, Inc. $NBIX](https://longbridge.com/en/news/284992055.md)